MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Xience V (Promus) Drug-Eluting Coronary Stent
Design features, preclinical data, and clinical outcomes.
By Krishna Sudhir, MD, PhD, FRACP, FACC; David R. Rutledge, Pharm D, FAHA, FCCP; Alena Pechonkina, MD; and Chuck Simonton, MD, FACC, FSCAI
SMT Supraflex Cruz DES for HBR Patients Evaluated in COMPARE RCT
October 16, 2024—Sahajanand Medical Technologies (SMT) announced results of the COMPARE 60/80 HBR trial evaluating the company’s Supraflex Cruz stent in high-bleeding-risk (HBR) patients.
